Tickers

1. Composite Trajectory Verdict

Given HCA's capital-intensive hospital operations with significant debt service and ongoing capital expenditure requirements, all three statements carry weight, but cash flow generation and balance sheet leverage are particularly critical for assessing financial flexibility and sustainability.

Composite Trajectory: Mixed

The annual income statement shows clear improvement: revenue grew 7.1% to $75.600 billion and net income attributable to HCA rose 17.8% to $6.784 billion in 2025 versus 2024 (10-K 2025, Operating Results Summary). Annual operating cash flow also improved strongly, rising 20.2% to $12.636 billion in 2025 (10-K 2025, Liquidity and Capital Resources). However, quarterly cash flow deteriorated sharply in the first half of 2026, with operating cash flow falling 25.8% year-over-year to $4.349 billion for the six months ended June 30, 2026, driven by a $1.099 billion unfavorable working capital shift and higher tax payments (10-Q Q2 2026, Liquidity and Capital Resources). The balance sheet shows rising leverage: total debt increased to $49.718 billion at June 30, 2026 from $46.492 billion at December 31, 2025, while the shareholders' deficit widened to -$6.642 billion from -$6.027 billion (10-Q Q2 2026, Balance Sheet; 10-K 2025, Balance Sheet). Working capital remained negative at -$122 million at June 30, 2026 (10-Q Q2 2026, Liquidity and Capital Resources). Quarterly net income margins also compressed: 8.4% in Q2 2026 versus 8.9% in Q2 2025 (10-Q Q2 2026, Operating Results Summary). Thus, annual earnings and cash flow trends are improving, but recent quarterly cash flow, margin compression, and balance sheet leverage are deteriorating.

2. Red Flags

• Quarterly operating cash flow declined $1.875 billion in Q2 2026 versus Q2 2025 (from $4.210 billion to $2.335 billion), primarily due to a $1.413 billion unfavorable working capital change including increased accounts receivable from Medicaid directed payment programs and a $594 million increase in income taxes paid related to an IRS deferral (10-Q Q2 2026, MD&A Operations Summary and Liquidity and Capital Resources).
• Working capital turned negative at -$567 million at December 31, 2025 versus +$1.237 billion at December 31, 2024, driven by an $893 million cash decline and a $1.173 billion increase in current liabilities including $2.207 billion of commercial paper (10-K 2025, Liquidity and Capital Resources).
• Short-term borrowings (commercial paper) surged to $2.207 billion at December 31, 2025 and $3.890 billion at June 30, 2026 (10-K 2025, Liquidity and Capital Resources; 10-Q Q2 2026, Liquidity and Capital Resources).
• Total debt rose to $49.718 billion at June 30, 2026 from $46.492 billion at December 31, 2025, a 6.9% increase in six months (10-Q Q2 2026, Liquidity and Capital Resources; 10-K 2025, Financing Activities).
• Shareholders' deficit attributable to HCA widened to -$6.642 billion at June 30, 2026 from -$6.027 billion at December 31, 2025 (10-Q Q2 2026, Balance Sheet; 10-K 2025, Balance Sheet).
• Quarterly net income margin compressed to 8.4% in Q2 2026 from 8.9% in Q2 2025, and year-to-date margin fell to 8.4% from 8.8% (10-Q Q2 2026, Operating Results Summary).
• Share repurchases of $10.067 billion in 2025 and $3.635 billion in the first half of 2026 were funded partly by debt issuance (10-K 2025, Liquidity and Capital Resources; 10-Q Q2 2026, Cash Flows from Financing Activities).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

On an annual basis, revenue increased 7.1% to $75.600 billion in 2025 from $70.603 billion in 2024, driven by a 2.9% rise in equivalent admissions and a 4.0% increase in revenue per equivalent admission (10-K 2025, Operating Results Summary). Net income attributable to HCA grew 17.8% to $6.784 billion ($28.33 diluted EPS) from $5.760 billion ($22.00 diluted EPS) in 2024 (10-K 2025, 2025 Operations Summary). Operating margins expanded: income before income taxes rose to 13.0% of revenue in 2025 from 12.1% in 2024 (10-K 2025, Operating Results Summary). Same-facility revenue grew 6.6% in 2025 (10-K 2025, Revenue/Volume Trends). Quarterly results for the first half of 2026 show revenue growth of 6.5% year-over-year to $39.339 billion, but net income attributable to HCA rose only 1.7% to $3.319 billion, with margins compressing to 8.4% from 8.8% (10-Q Q2 2026, Operating Results Summary). The annual trend is clearly improving; the recent quarterly margin pressure does not yet offset the multi-year improvement.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Annual operating cash flow has grown consistently: $12.636 billion in 2025, up 20.2% from $10.514 billion in 2024, which was up 11.5% from $9.431 billion in 2023 (10-K 2025, Liquidity and Capital Resources). Free cash flow (operating cash flow less capital expenditures excluding acquisitions) increased to approximately $7.7 billion in 2025 from $5.6 billion in 2024 (derived from 10-K 2025, Liquidity and Capital Resources). However, quarterly operating cash flow deteriorated markedly in the first half of 2026: $4.349 billion for the six months ended June 30, 2026 versus $5.861 billion for the same period in 2025, a 25.8% decline (10-Q Q2 2026, Liquidity and Capital Resources). The decline was driven by a $1.099 billion unfavorable working capital change (primarily increased accounts receivable from Medicaid directed payment programs) and a $579 million increase in income tax payments (10-Q Q2 2026, Liquidity and Capital Resources). Q2 2026 alone saw operating cash flow of $2.335 billion versus $4.210 billion in Q2 2025 (10-Q Q2 2026, MD&A Operations Summary). Capital expenditures remained elevated at $2.350 billion for the first half of 2026 (10-Q Q2 2026, Liquidity and Capital Resources).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Total debt increased from $43.031 billion at December 31, 2024 to $46.492 billion at December 31, 2025, and further to $49.718 billion at June 30, 2026 (10-K 2025, Financing Activities; 10-Q Q2 2026, Liquidity and Capital Resources). The shareholders' deficit attributable to HCA widened from -$2.499 billion at December 31, 2024 to -$6.027 billion at December 31, 2025, and to -$6.642 billion at June 30, 2026 (10-K 2025, Balance Sheet; 10-Q Q2 2026, Balance Sheet). Cash and cash equivalents declined from $1.933 billion at December 31, 2024 to $1.040 billion at December 31, 2025, and to $1.013 billion at June 30, 2026 (10-K 2025, Balance Sheet; 10-Q Q2 2026, Balance Sheet). Working capital was negative at -$567 million at December 31, 2025 and -$122 million at June 30, 2026 (10-K 2025, Liquidity and Capital Resources; 10-Q Q2 2026, Liquidity and Capital Resources). Short-term borrowings (primarily commercial paper) rose from zero at December 31, 2024 to $2.207 billion at December 31, 2025 and $3.890 billion at June 30, 2026 (10-K 2025, Liquidity and Capital Resources; 10-Q Q2 2026, Liquidity and Capital Resources). While the company maintains access to an $8.0 billion senior unsecured credit facility ($3.086 billion available at June 30, 2026 after backstopping commercial paper), leverage and balance sheet risk metrics are trending unfavorably.

6. Data Gaps

• Standalone Q1 2026 income statement and cash flow statement (only year-to-date and Q2 2026 figures provided in 10-Q Q2 2026).
• Full quarterly financial statements for Q3 2025 and Q4 2025 (10-Q for Q3 2025 provided only operating data table, not full financial statements).
• Detailed breakdown of accounts receivable increase attributable to Medicaid directed payment programs versus other payers.
• Scheduled debt maturities for the next 12-24 months beyond the commercial paper program.
• Impact of the Florida directed payment program on full-year 2026 revenue and cash flow (only partial quarter impact disclosed).